Add Tribune As Your Trusted Source
TrendingVideosIndia
Opinions | CommentEditorialsThe MiddleLetters to the EditorReflections
UPSC | Exam ScheduleExam Mentor
State | Himachal PradeshPunjabJammu & KashmirHaryanaChhattisgarhMadhya PradeshRajasthanUttarakhandUttar Pradesh
City | ChandigarhAmritsarJalandharLudhianaDelhiPatialaBathindaShaharnama
World | ChinaUnited StatesPakistan
Diaspora
Features | The Tribune ScienceTime CapsuleSpectrumIn-DepthTravelFood
Business | My Money
News Columns | Straight DriveCanada CallingLondon LetterKashmir AngleJammu JournalInside the CapitalHimachal CallingHill ViewBenchmark
Don't Miss
Advertisement

Covid: DCGI panel clears Corbevax for 12-18 age group

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Yearly Premium ₹999 ₹349/Year
Yearly Premium $49 $24.99/Year
Advertisement

New Delhi, February 14

Advertisement

The subject experts committee of the Drug Controller General of India (DCGI) has recommended granting emergency use authorisation to Biological E’s Covid vaccine for 12 to 18-year-olds.

Advertisement

The DCGI had on December 28 last year approved Corbevax, which is India’s first indigenous RBD protein sub-unit vaccine, for restricted use in emergency situation in adults. It has not been included in the country’s vaccination drive yet. The government is yet to take a decision on vaccinating those aged below 15 years.

Advertisement
Show comments
Advertisement